The third stage of clinical trials of a COVID-19 vaccine developed by the Chinese Anhui Zhifei Longcom Biopharmaceutical has begun in Uzbekistan, with 5,000 local volunteers participating, the press service of the Uzbek Ministry of Innovative Development said on Thursday.
Earlier in November, the Ministry of Innovations announced that Uzbek specialists had begun clinical trials of the Chinese vaccine. Also, Uzbekistan intends to test other coronavirus vaccines developed in Russia and Turkey.
Uzbekistan estimates that by June 2021 it should be able to vaccinate up to 60 percent of the population of the country against COVID-19.
“The Ministry of Innovation Development and the Ministry of Health have begun the third phase of clinical trials of the coronavirus vaccine developed by Zhifei Longcom Biopharmaceutical Co., Ltd. based on the development of the Institute of Microbiology of the Chinese Academy of Sciences,” the ministry said in a statement on its website.
Last week, Russian Trade Minister Denis Manturov delivered 100 doses of the Russian Sputnik V vaccine against coronavirus to Tashkent intended for phase 3 trials. A representative of the Sanitary and Epidemiological Welfare and Public Health Service of Uzbekistan told Sputnik that the authorities would soon make a decision on the use of the received batch of vaccines.